抗抑郁药治疗选择的药物基因组学检测：经验教训和前进路线。
Pharmacogenomic testing for antidepressant treatment selection: lessons learned and roadmap forward.
机构信息
Department of Psychiatry & Psychology, Mayo Clinic, Mayo Clinic Alix School of Medicine, Rochester, MN, USA.
Department of Psychiatry & Behavioral Sciences, University of Texas at Austin Dell Medical School, Austin, TX, USA.
出版信息
Neuropsychopharmacology. 2024 Jan;49(1):282-284. doi: 10.1038/s41386-023-01667-4. Epub 2023 Aug 7.
Abstract
Pharmacogenomic technology is a developing field with enthusiastic interest and broad application potential. Three large, controlled studies have been published exploring the benefit of pharmacogenomically guided antidepressant treatment selection. Though all three studies did not show significant benefit of using this technology, these studies laid the foundation for further research that should address the limitations of this previous research and currently available commercial platforms. Future research needs to include large scale pharmacogenomic trials with GWAS analytics across diverse groups with attention to cost-effectiveness models, particularly for cases of treatment resistance and polypharmacy. The application of results from these large scale pharmacogenomic trials must also include exploring optimal EHR user interface design.
摘要
药物基因组学技术是一个充满热情和广泛应用潜力的发展领域。已经发表了三项大型对照研究，探索了基于药物基因组学的抗抑郁药治疗选择的益处。尽管这三项研究都没有显示出使用这项技术的显著益处，但这些研究为进一步研究奠定了基础，应该解决之前研究和当前可用商业平台的局限性。未来的研究需要包括大规模的药物基因组学试验，使用全基因组关联分析（GWAS）在不同群体中进行，同时要注意成本效益模型，特别是对于治疗抵抗和多药治疗的情况。这些大规模药物基因组学试验结果的应用还必须包括探索最佳的电子健康记录（EHR）用户界面设计。
相似文献
1
Pharmacogenomic testing for antidepressant treatment selection: lessons learned and roadmap forward.抗抑郁药治疗选择的药物基因组学检测：经验教训和前进路线。
Neuropsychopharmacology. 2024 Jan;49(1):282-284. doi: 10.1038/s41386-023-01667-4. Epub 2023 Aug 7.
2
Dynamic and accessible pharmacogenomic results: a response to pharmacogenomic testing for antidepressant treatment selection.动态且易于获取的药物基因组学结果：对抗抑郁治疗选择的药物基因组学检测的回应
Neuropsychopharmacology. 2024 Apr;49(5):769. doi: 10.1038/s41386-024-01816-3. Epub 2024 Feb 10.
3
Reply to Sun: Dynamic and accessible pharmacogenomic results: a response to pharmacogenomic testing for antidepressant treatment selection.对孙的回复：动态且可获取的药物基因组学结果：对抗抑郁药治疗选择的药物基因组学检测的回应。
Neuropsychopharmacology. 2024 Apr;49(5):770-771. doi: 10.1038/s41386-024-01815-4. Epub 2024 Feb 15.
4
Effect of Pharmacogenomic Testing for Drug-Gene Interactions on Medication Selection and Remission of Symptoms in Major Depressive Disorder: The PRIME Care Randomized Clinical Trial.药物基因相互作用的药物基因组检测对重度抑郁症患者药物选择和症状缓解的影响：PRIME Care 随机临床试验。
JAMA. 2022 Jul 12;328(2):151-161. doi: 10.1001/jama.2022.9805.
5
Multi-gene Pharmacogenomic Testing That Includes Decision-Support Tools to Guide Medication Selection for Major Depression: A Health Technology Assessment.多基因药物基因组学检测，包括用于指导抗抑郁药物选择的决策支持工具：一项卫生技术评估。
Ont Health Technol Assess Ser. 2021 Aug 12;21(13):1-214. eCollection 2021.
6
The effect of pharmacogenomic testing on response and remission rates in the acute treatment of major depressive disorder: A meta-analysis.基于药物基因组学检测对治疗重度抑郁症急性期反应和缓解率的影响：一项荟萃分析。
J Affect Disord. 2018 Dec 1;241:484-491. doi: 10.1016/j.jad.2018.08.056. Epub 2018 Aug 14.
7
Pharmacogenomic Testing for Selection of Antidepressant Provides Minimal, If Any, Benefit.用于选择抗抑郁药的药物基因组学检测益处极小（若有任何益处的话）。
Am Fam Physician. 2023 Jan;107(1):97-98.
8
and Variant Coverage of Commercial Antidepressant Pharmacogenomic Testing Panels Available in Victoria, Australia.以及澳大利亚维多利亚州商业抗抑郁药药物基因组学检测面板的变异覆盖情况。
Genes (Basel). 2023 Oct 16;14(10):1945. doi: 10.3390/genes14101945.
9
Pharmacogenomic Testing for Next-Step Antidepressant Selection: Still a Work in Progress.用于下一步抗抑郁药选择的药物基因组学检测：仍在进展中。
JAMA. 2022 Jul 12;328(2):146-148. doi: 10.1001/jama.2022.10018.
10
Assessing the impact of pre-test education on patient knowledge, perceptions, and expectations of pharmacogenomic testing to guide antidepressant use.评估预测试教育对患者关于药物基因组学检测以指导抗抑郁药使用的知识、认知和期望的影响。
J Genet Couns. 2022 Dec;31(6):1373-1382. doi: 10.1002/jgc4.1612. Epub 2022 Jul 28.
引用本文的文献
1
Comprehensive Characterization of Antidepressant Pharmacogenetics: A Systematic Review of Studies in Major Depressive Disorder.抗抑郁药物遗传学的全面特征：对重度抑郁症研究的系统评价
Clin Transl Sci. 2025 Jun;18(6):e70255. doi: 10.1111/cts.70255.
2
The Perceived Value of Pharmacogenetic Testing in Depression Treatment: Mixed-Methods Results From the PRIME Care Study.药物基因检测在抑郁症治疗中的感知价值：PRIME 护理研究的混合方法结果
Psychiatr Serv. 2025 Jun 1;76(6):589-597. doi: 10.1176/appi.ps.20240080. Epub 2025 Apr 16.
3
Pharmacogenomic augmented machine learning in electronic health record alerts: A health system-wide usability survey of clinicians.基于药物基因组学增强的机器学习在电子健康记录警报中的应用：一项针对临床医生的全健康系统可用性调查。
Clin Transl Sci. 2024 Oct;17(10):e70044. doi: 10.1111/cts.70044.
4
Rationale and design for a pragmatic randomized trial to assess gene-based prescribing for SSRIs in the treatment of depression.为评估基于基因的 SSRIs 处方治疗抑郁症的实用性随机试验的原理和设计。
Clin Transl Sci. 2024 Jun;17(6):e13822. doi: 10.1111/cts.13822.
5
Dynamic and accessible pharmacogenomic results: a response to pharmacogenomic testing for antidepressant treatment selection.动态且易于获取的药物基因组学结果：对抗抑郁治疗选择的药物基因组学检测的回应
Neuropsychopharmacology. 2024 Apr;49(5):769. doi: 10.1038/s41386-024-01816-3. Epub 2024 Feb 10.
本文引用的文献
1
Effect of Pharmacogenomic Testing for Drug-Gene Interactions on Medication Selection and Remission of Symptoms in Major Depressive Disorder: The PRIME Care Randomized Clinical Trial.药物基因相互作用的药物基因组检测对重度抑郁症患者药物选择和症状缓解的影响：PRIME Care 随机临床试验。
JAMA. 2022 Jul 12;328(2):151-161. doi: 10.1001/jama.2022.9805.
2
A Randomized Controlled Trial of Combinatorial Pharmacogenetics Testing in Adolescent Depression.青少年抑郁症的组合式药物遗传学检测的随机对照试验。
J Am Acad Child Adolesc Psychiatry. 2022 Jan;61(1):46-55. doi: 10.1016/j.jaac.2021.03.011. Epub 2021 Jun 5.
3
Randomized, controlled, participant- and rater-blind trial of pharmacogenomic test-guided treatment versus treatment as usual for major depressive disorder.随机、对照、参与者和评估者双盲试验：基于药物基因组学检测的治疗与常规治疗重度抑郁症的比较。
Depress Anxiety. 2020 Sep;37(9):834-841. doi: 10.1002/da.23029. Epub 2020 May 7.
4
Comparing sensitivity to change using the 6-item versus the 17-item Hamilton depression rating scale in the GUIDED randomized controlled trial.在 GUIDED 随机对照试验中，使用 6 项和 17 项汉密尔顿抑郁量表评估变化敏感性的比较。
BMC Psychiatry. 2019 Dec 27;19(1):420. doi: 10.1186/s12888-019-2410-2.
5
Impact of Pharmacogenomics on Clinical Outcomes for Patients Taking Medications With Gene-Drug Interactions in a Randomized Controlled Trial.随机对照试验中药物基因组学对具有基因-药物相互作用的药物治疗患者临床结局的影响。
J Clin Psychiatry. 2019 Oct 31;80(6):19m12910. doi: 10.4088/JCP.19m12910.
6
Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial: A large, patient- and rater-blinded, randomized, controlled study.在 GUIDED 试验中，药物基因组学对重度抑郁症临床结局的影响：一项大型、患者和评定者设盲、随机、对照研究。
J Psychiatr Res. 2019 Apr;111:59-67. doi: 10.1016/j.jpsychires.2019.01.003. Epub 2019 Jan 4.
7
Pharmacokinetic-Pharmacodynamic interaction associated with venlafaxine-XR remission in patients with major depressive disorder with history of citalopram / escitalopram treatment failure.与文拉法辛-XR 缓解与有西酞普兰/艾司西酞普兰治疗失败史的重性抑郁障碍患者相关的药代动力学-药效学相互作用。
J Affect Disord. 2019 Mar 1;246:62-68. doi: 10.1016/j.jad.2018.12.021. Epub 2018 Dec 17.
8
Clinical Implementation of Pharmacogenetic Decision Support Tools for Antidepressant Drug Prescribing.临床实施抗抑郁药处方药物基因组学决策支持工具。
Am J Psychiatry. 2018 Sep 1;175(9):873-886. doi: 10.1176/appi.ajp.2018.17111282. Epub 2018 Apr 25.
9
Antidepressant Outcomes Predicted by Genetic Variation in Corticotropin-Releasing Hormone Binding Protein.促肾上腺皮质激素释放激素结合蛋白基因变异预测抗抑郁药的疗效。
Am J Psychiatry. 2018 Mar 1;175(3):251-261. doi: 10.1176/appi.ajp.2017.17020172. Epub 2017 Dec 15.
10
ABCB1 Genetic Effects on Antidepressant Outcomes: A Report From the iSPOT-D Trial.ABCB1 基因对抗抑郁药疗效的影响：来自 iSPOT-D 试验的报告。
Am J Psychiatry. 2015 Aug 1;172(8):751-9. doi: 10.1176/appi.ajp.2015.14050680. Epub 2015 Mar 27.
Zotero 插件